These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34849917)

  • 1. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.
    Kjeldsen S; Nielsen J; Mertz Nørgård B; Kjeldsen J
    Inflamm Bowel Dis; 2022 Oct; 28(10):1513-1519. PubMed ID: 34849917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
    Seo J; Kim S; Hong SW; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Kim YJ; Ye BD
    Aliment Pharmacol Ther; 2024 Aug; 60(3):389-400. PubMed ID: 38866064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.
    Razik R; Rumman A; Bahreini Z; McGeer A; Nguyen GC
    Am J Gastroenterol; 2016 Aug; 111(8):1141-6. PubMed ID: 27215924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
    Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
    [No Abstract]   [Full Text] [Related]  

  • 8. The Prevalence of Inflammatory Bowel Disease in Greenland.
    Gantzel RH; Vesterdal JD; Haase AM; Petersen AJ; Grønbæk H; Pedersen ML
    Inflamm Bowel Dis; 2023 Dec; 29(12):1879-1885. PubMed ID: 36702537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
    Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends and Outcomes of Hip Fracture Hospitalization Among Medicare Beneficiaries with Inflammatory Bowel Disease, 2000-2017.
    Xu F; Wheaton AG; Barbour KE; Liu Y; Greenlund KJ
    Dig Dis Sci; 2021 Jun; 66(6):1818-1828. PubMed ID: 32700169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Bowel Disease Does Not Impact Mortality but Increases Length of Hospitalization in Patients with Acute Myocardial Infarction.
    Sinh P; Tabibian JH; Biyani PS; Mehta K; Mansoor E; Loftus EV; Dave M
    Dig Dis Sci; 2021 Dec; 66(12):4169-4177. PubMed ID: 33492533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
    Pearce CB; Duncan HD; Timmis L; Green JR
    Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil.
    Zaltman C; Parra RS; Sassaki LY; Santana GO; Ferrari MLA; Miszputen SJ; Amarante HMBS; Kaiser Junior RL; Flores C; Catapani WR; Parente JML; Bafutto M; Ramos O; Gonçalves CD; Guimaraes IM; da Rocha JJR; Feitosa MR; Feres O; Saad-Hossne R; Penna FGC; Cunha PFS; Gomes TN; Nones RB; Faria MAG; Parente MPPD; Scotton AS; Caratin RF; Senra J; Chebli JM
    World J Gastroenterol; 2021 Jan; 27(2):208-223. PubMed ID: 33510560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
    Ungaro RC; Kadali H; Zhang W; Adsul S; Reinisch W
    J Crohns Colitis; 2023 Dec; 17(12):1949-1961. PubMed ID: 37492976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases - A Danish Prospective Population-Based Cohort Study with Individual-Level Data.
    Attauabi M; Dahlerup JF; Poulsen A; Hansen MR; Vester-Andersen MK; Eraslan S; Prahm AP; Pedersen N; Larsen L; Jess T; Neumann A; Haderslev KV; Molazahi A; Lødrup AB; Glerup H; Oppfeldt AM; Jensen MD; Theede K; Kiszka-Kanowitz M; Seidelin JB; Burisch J
    J Crohns Colitis; 2022 Jun; 16(5):757-767. PubMed ID: 34755858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.
    Jairath V; Hokkanen SRK; Guizzetti L; Boxall N; Campbell-Hill S; Patel H
    Aliment Pharmacol Ther; 2019 Aug; 50(4):416-424. PubMed ID: 31298421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Does Not Lead to an Increase in Corticosteroid Prescriptions in IBD Patients: A Nationwide Cohort Study.
    Nørgård BM; Zegers FD; Nielsen J; Knudsen T; Kjeldsen J
    Inflamm Bowel Dis; 2023 Sep; 29(9):1470-1476. PubMed ID: 37067508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.